Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005

被引：0
|
作者：
Wisniewski, Mathilde [1 ]
Placide, Pierre-Alain [1 ]
Granier, Sandra [1 ]
Al Shatti, Yacoub [1 ]
Al Qalaf, Shuaib [1 ]
Bouattour, Mohamed [1 ]
Lamuraglia, Michele [1 ]
Hammel, Pascal [1 ]
机构：
[1] Univ Denis Diderot Paris VII, AP HP, Hop Beaujon, Dept Digest & Med Oncol, Clichy, France
来源：
HEPATOBILIARY SURGERY AND NUTRITION | 2018年 / 7卷 / 05期
关键词：
RANDOMIZED CONTROLLED-TRIAL; CANCER; CHEMORADIOTHERAPY; MULTICENTER;
D O I：
10.21037/hbsn.2018.08.03
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：399 / 402
页数：4
相关论文
共 50 条
  • [31] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Sung Kyu
    Hong, Dae Sik
    Choi, Hyun Jong
    Moon, Jong Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [32] Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG].
    Moore, MJ
    Goldstein, D
    Hamm, J
    Figer, A
    Hecht, J
    Gallinger, S
    Au, H
    Ding, K
    Christy-Bittel, J
    Parulekar, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1S - 1S
  • [33] A randomized phase II trial of neoadjuvant chemotherapy for patients with resectable pancreatic cancer: Gemcitabine alone vs. gemcitabine combined with cisplatin.
    Palmer, DH
    Stocken, DD
    Buckels, JAC
    Hewitt, H
    Markham, CE
    Mirza, D
    Johnson, PJ
    Hassan, AB
    Bramhall, SR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 367S - 367S
  • [34] APACT: Phase III, Multicenter, International, Open-Label, Randomized Trial of Adjuvant nab-Paclitaxel Plus Gemcitabine (nab-P/G) Versus Gemcitabine (G) for Surgically Resected Pancreatic Adenocarcinoma
    Ko, A.
    Reni, M.
    Riess, H.
    Pelzer, U.
    O'Reilly, E. M.
    Winter, J.
    Oh, D. Y.
    Li, C. P.
    Tortora, G.
    Chang, H. M.
    Lopez, C. D.
    Tabernero, J.
    Van Cutsem, E.
    Philip, P.
    Goldstein, D.
    Berlin, J. D.
    Ferrara, S.
    Li, M.
    Lu, B.
    Romano, A.
    Marks, H.
    Biankin, A.
    Tempero, M. A.
    PANCREAS, 2019, 48 (10) : 1464 - 1464
  • [35] ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.
    Neoptolemos, John P.
    Palmer, Daniel H.
    Ghaneh, Paula
    Valle, Juan W.
    Cunningham, David
    Wadsley, Jonathan
    Meyer, Tim
    Anthoney, Alan
    Glimelius, Bengt
    Falk, Stephen
    Segersvard, Ralf
    Middleton, Gary William
    Ross, Paul J.
    Wasan, Harpreet Singh
    McDonald, Alec
    Crosby, Tom David Lewis
    Psarelli, Eftychia Eirini
    Hammel, Pascal
    Hackert, Thilo
    Buchler, Markus W.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727).
    Philip, Philip Agop
    Goldman, Bryan H.
    Ramanathan, Ramesh K.
    Lenz, Heinz-Josef
    Lowy, Andrew M.
    Whitehead, Robert P.
    Iqbal, Syma
    Gaur, Rakesh
    Benedetti, Jacqueline K.
    Blanke, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [37] Original Research Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma-A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials
    Kurreck, Annika
    Weckwerth, Johanna
    Modest, Dominik P.
    Striefler, Jana K.
    Bahra, Marcus
    Bischoff, Sven
    Pelzer, Uwe
    Oettle, Helmut
    Kruger, Stephan
    Riess, Hanno
    Sinn, Marianne
    EUROPEAN JOURNAL OF CANCER, 2021, 150 : 250 - 259
  • [38] Phase II trial of postoperative adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiation with gemcitabine in patients with resected pancreatic cancer.
    Kwon, J. H.
    Chie, E. K.
    Kim, J. H.
    Im, S.
    Oh, D.
    Kim, Y.
    Han, S.
    Lee, K.
    Jang, J.
    Kim, T.
    Kim, J. S.
    Han, H. S.
    Kim, S.
    Yoon, Y. B.
    Bang, Y.
    Ha, S. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer (vol 18, pg 1122, 2011)
    Bao, Philip Q.
    Ramanathan, Ramesh K.
    Krasinkas, Alyssa
    Bahary, Nathan
    Lembersky, Barry C.
    Bartlett, David L.
    Hughes, Steven J.
    Lee, Kenneth K.
    Moser, A. James
    Zeh, Herbert J., III
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 : S323 - S323
  • [40] Perioperative Gemcitabine plus Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial
    Wei, Alice C.
    Ou, Fang-Shu
    Shi, Qian
    Carrero, Xiomara
    O'Reilly, Eileen M.
    Meyerhardt, Jeffrey
    Wolff, Robert A.
    Kindler, Hedy L.
    Evans, Douglas B.
    Deshpande, Vikram
    Misdraji, Joseph
    Tamm, Eric
    Sahani, Dushyant
    Moore, Malcolm
    Newman, Elliot
    Merchant, Nipun
    Berlin, Jordan
    Goff, Laura W.
    Pisters, Peter
    Posner, Mitchell C.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (13) : 4489 - 4497
12345